$0.34
▼ -0.8% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
--HC Wainwright Downgrades Heron Therapeutics to Neutral From Buy
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
Overview
52-week range
$0.30
$1.58
3% of range
Avg surprise (last 3)
+22.2%
Avg reaction (last 2)
-3.5%
50% positive
Latest IV / EM
651%
EM ±101.8% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.03 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.04 | $-0.03 | -33.3% | -500.0% | -20.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.10 | — | — | — | — | financials |
| Fri Aug 8, 2025 | Jun/2025 | $-0.02 | $-0.01 | -100.0% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $0.01 | $-0.01 | +200.0% | — | +13.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.03 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.06 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.02 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.17 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.35 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.27 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38M | $35M | — | $38M | $37M | $39M | — | $33M |
| Cost of revenue | $12M | $11M | — | $12M | $10M | $8M | — | $9M |
| Gross profit | $26M | $24M | — | $26M | $27M | $30M | — | $23M |
| Operating income | $-2M | $-5M | — | $-4M | $-2M | $3M | — | $-4M |
| Net income | $-5M | $-8M | — | $-17M | $-2M | $3M | — | $-5M |
| EPS (diluted) | $-0.03 | $-0.04 | — | $-0.10 | $-0.02 | $0.01 | — | $-0.03 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21M | $26M | $29M | $43M | $17M | $19M | $26M | $26M |
| Inventory | $91M | $93M | $93M | $70M | $73M | $57M | $53M | $46M |
| Total current assets | $230M | $229M | $238M | $229M | $211M | $213M | $209M | $195M |
| Total assets | $252M | $246M | $256M | $249M | $232M | $236M | $233M | $221M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $245M | $237M | $242M | $234M | $259M | $264M | $267M | $261M |
| Total equity | $7M | $9M | $14M | $15M | $-27M | $-28M | $-34M | $-40M |